Unlearn.AI的动态

???Listen to?Dr. Mark Murcko in our Inaugural 2024 Kitchen Table Talk! Dewpoint scientists hosted experienced drug-hunter Dr. Mark Murcko to kick off our 2024 Kitchen Table Talk series. Dr. Murcko delves into the evolution of drug discovery strategies and how adopting a condensate mindset can transform the way we develop future therapies. Check out the audiogram below for a glimpse into the discussion, and?learn?how insights into aberrant #condensates?and their relationship to disease?are reshaping our understanding of disease mechanisms?and strategies for drug discovery. ???Watch the full discussion here:?https://bit.ly/3VB9Dak #DiscoverCondensates

Part of Secondary Prevention in my eyes = Early accurate Multi-organ Clinical assessment (Opportunity) & Diagnostics ... to enable Early and efficacious Multi-organ Disease Management...

As your research expands and scales, our solutions are designed to grow with you. Invitrogen? NuPAGE? Bis-Tris, Tris-Glycine, and Tris-Acetate Midi WedgeWell? Format Gels enable you to load up to 26 samples per gel with double the volume, all without compromising on separation performance. Gather more data in less time, all while reducing costs and enhancing reproducibility. In rapidly evolving research fields like disease modeling and drug discovery, scalability is crucial. But don't worry, we are here to grow with you. Scale up with the Midi WedgeWell Format Gels: https://lnkd.in/dtmuPM_T

We were honored to host Dr. Ruogang Zhao from the University at Buffalo for an enlightening?talk on “Engineered Fibrotic Tissue Models for Disease Modeling and Drug Testing.” The event was a great success, and we deeply valued Dr. Zhao's knowledge and insights. Thank you, Dr. Zhao, for sharing your expertise with us! #RensselaerPolytechnicInstitute, #NIHT32Grant, #ResearchFellowship, #RPIGraduateStudents #Seminar #TissueEngineering #DiseaseModeling #DrugTesting #Research #BiomedicalScience #ResearchTalk #ScientificCommunity #DrugTesting #FibroticTissue

Today marks Rare Disease Day; a day to focus on social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. At Target ALS, our commitment to realizing a world where #EveryoneLives means we advance research for all people living with ALS, including those with the rarest forms of the disease. Through collaborative efforts with esteemed partners such as n-Lorem Foundation, we are pioneering therapeutic avenues for nano-rare ALS mutations, marking significant progress on a patient-centric trajectory. Together, with aligned organizational core values, we're advancing the frontier of drug discovery tailored to ultra-rare forms of ALS, fueled by a shared philosophy and a concerted mission to drive scientific innovation. #RareDiseaseDay #ALSResearch #ScientificAdvancements #EndALS #RareDisease Sarah Glass, PhD

?????? ?????????????????????? ???????????????? ?????????? ?????? ?????? ???????? ???? ????????-?????????????????? ???????????????? ???????? ???????????? ?? The ALLTogether clinical trial aims to enhance both the survival rate and quality of life for patients with acute lymphoblastic leukaemia (#ALL). By establishing an optimised diagnostic algorithm, the trial facilitates the best treatment decisions. Learn more about this groundbreaking trial and discover how IVDR-certified CytoCell FISH probes integrate into the diagnostic process here ?? https://lnkd.in/d2xvZpqD #Sysmex

Watch this video, where Prof. Sylvain Lehmann shares insights on the impact of biomarker diagnostics in #AlzheimersDisease and why a timely diagnosis is vital.1?3 #ADPD24. For Healthcare professionals.

In 2024, new paths are being uncovered in endometriosis care. From advanced treatments to cutting-edge diagnostics, let's explore the promising insights into endometriosis research and the possible challenges ahead. #womensawarenessmonth https://hubs.li/Q02r4Wpf0

Today, there is an interesting article on the New York Times, “All the Alzheimer’s Research We Didn’t Do”, e.g., is Hydroxychloroquine useful for AD patients? Some experts guess so. But designing a rigorous clinical trial to test this hypothesis is almost impossible, at least in the near future, when A-beta hypothesis still dominates. Then, how about RWE? In patients with SLE, the risk of Alzheimer's disease was 1.4 times higher than non-SLE control. Hydroxychloroquine is approved for the treatment of SLE. Does Hydroxychloroquine slow down early AD progress for SLE patients in real world? My point is, when formal clinical trials are not possible, we may think about RWE instead, to explore our hypothesis.

My PhD thesis work focused on studying the impact of bacterial functional amyloids, like CsgA, in Parkinson's disease causation. Extremely delighted to see that novel therapeutics are being developed to target the gut-brain-axis in neurodegenarative diseases. #gutmicrobiome #gutbrainaxis #neurodegeneration #parkinsonsdisease #alzheimersdisease